Avior Wealth Management LLC Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Avior Wealth Management LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 12.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,745 shares of the life sciences company’s stock after acquiring an additional 418 shares during the quarter. Avior Wealth Management LLC’s holdings in Illumina were worth $521,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Acadian Asset Management LLC increased its holdings in Illumina by 312.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after buying an additional 1,525 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Illumina by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock valued at $82,853,000 after acquiring an additional 7,114 shares during the last quarter. Dakota Wealth Management grew its stake in shares of Illumina by 13.8% in the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares during the period. Sequoia Financial Advisors LLC raised its holdings in shares of Illumina by 16.9% during the first quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after purchasing an additional 116 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its position in Illumina by 10.2% during the first quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after purchasing an additional 4,548 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research analyst reports. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Barclays lifted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Trading Down 1.4 %

Shares of Illumina stock opened at $116.69 on Friday. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $232.23. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average of $133.78 and a 200 day moving average of $128.07.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 earnings per share. On average, equities analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.